Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 780-782

  Jiang, Xiaosui ^a   Crain, Earl J ^a   Luettgen, Joseph M ^a   Schumacher, William A ^a   Wong, Pancras C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRIN; PROTHROMBIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ATRIUM FIBRILLATION; HUMAN; IC 50; IN VITRO STUDY; INCUBATION TIME; LETTER; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; SECONDARY PREVENTION; SPECIES DIFFERENCE; STROKE; THERAPY EFFECT; THROMBOCYTE POOR PLASMA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; PEPTIDE FRAGMENTS; PROTHROMBIN; PYRAZOLES; PYRIDONES; THROMBOSIS;

EID: 64849114048     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0486     Document Type: Letter

References (16)

1. Eisenberg PR, Siegel JE, Abendschein DR, et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883.
2. Herault JP, Bernat A, Pflieger AM, et al. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22.
3. Meddahi S, Bara L, Fessi H, et al. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation. Blood Coagul Fibrinolysis 2005; 16: 125-133.
4. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391.
5. Sinha U, Lin PH, Edwards ST, et al. Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors. Arterioscler Thromb Vasc Biol 2003; 23: 1098-1104.
6. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of l-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidinl-yl)phenyl)-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-5356.
7. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-829.
8. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008; 6:1736-1741.
9. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
10. Büller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318
11. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-174.
12. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623.
13. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996; 16: 1285-1291
14. Kotze HF, Lamprecht S, Badenhorst PN, et al. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb Haemost 1997; 77: 1137-1142.
15. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939 - a novel, oral, direct factor Xa inhibitor - on clot-bound factor Xa activity in vitro. J Thromb Haemost 2005; 3 (Suppl 1): Abstract P1104.
16. Wong PC, Crain EJ, Pinto DJ, et al. Dose-dependent antithrombotic effects of apixaban, an oral direct factor Xa inhibitor, in prevention and treatment of thrombosis in rabbit models of arteriovenous-shunt and venous thrombosis at doses that preserve hemostasis. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 933.